Breast Cancer

Philadelphia Hormone Therapy Trial Completed

Published in Drug Law Weekly, March 6th, 2007

Wyeth (NYSE:WYE) announced that the jury in the case of Jennie Nelson v. Wyeth, in the Philadelphia Court of Common Pleas, found in favor of the plaintiffs and awarded damages of $3 million. Wyeth plans to appeal.

"We respectfully disagree that there is any scientific basis to support the jury's finding of a causal link between Wyeth's hormone therapies and the plaintiff's breast cancer," says Barbara R. Binis, a partner with Reed Smith LLP, a firm representing Wyeth in the case. "Further, the evidence established that Wyeth acted responsibly by performing and supporting studies that examined the known and potential benefits and risks of hormone therapy and by keeping...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2007-03-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry